Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (23483)	4/18/2007 9:35:26 AM
From: NeuroInvestment	Read Replies (3) \| Respond to of 52153

Rick: I don't know anyone--in print anyways-- who has been more consistently scathing about the Pharma Industry's pathetic embrace of the redundant than I have been, and my first reaction to that news was: Maybe this will force them to rejigger their strategic priorities. But I can't go along with the notion that the FDA is the 'instrument' with which to do so. Who decides how many is enough? Who decides that the various permutations of patient subgroups are adequately covered by the variety of 'me-toos' in existence?--and on what basis... I hope that this sufficiently scares the industry that they will recalibrate how to spend their resources--certainly shaming them hasn't worked. But putting it into regulatory practice to my mind is inviting overkill. Harry NeuroInvestment